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0. Summary 
National Profile 
The current National Drugs Strategy (2009 to 2016) sets out a range of priorities, each with 
associated actions, for drug treatment. The over-arching categories are development of general 
problem drug use treatment services; targeting of services for specific at-risk groups; development 
of a quality and standards framework; and training and skills development. The Health Service 
Executive (HSE) is responsible for the provision of all publicly funded drug treatment.  Drug 
treatment is therefore provided through a network of HSE services (public), but also non-
statutory/voluntary agencies, many of which are funded by the HSE.   Some private organisations 
also provide treatment.   
 
In 1998 a methadone treatment protocol (MTP) was introduced to ensure that treatment for problem 
opiate use could be provided wherever the demand existed.  Outpatient methadone treatment for 
problem opiate users is provided only through specialised HSE outpatient drug treatment clinics, 
satellite clinics or through specialised general practitioners (GPs) in the community.  Almost all 
opiate substitution treatment (OST) provided is methadone.  Buprenorphine in combination 
preparations is not routinely available in Ireland. 
 
Trends 
The majority of drug treatment (over 75%) is provided through publicly funded and voluntary out-
patient services.  Outpatient services include low threshold and specialised OST GPs in the 
community.  In-patient treatment is mainly provided through residential centres run by voluntary 
agencies.    The proportion of clients attending in-patient services (excluding prisons) has dropped 
slightly over the past 11 years from 15% in 2004 to 14% in 2014. 
 
Opiates (mainly heroin) are the main problem drug used by entrants to treatment, followed by 
cannabis and cocaine.  The proportion of all entrants to treatment reporting an opiate as their main 
problem drug has decreased year-on-year since 2004, from a peak of 65% in 2004 to 50% in 2014.  
Over the period, cannabis has been consistently reported as the second most common main 
problem drug, with the proportion increasing from 21% in 2004 to 28% in 2014.  The numbers 
presenting for treatment for problem cocaine use was highest in 2007 at 13%, dropping steadily until 
2012, but increasing again in 2014 to 9%.  For new clients to treatment, cannabis has been the 
main problem drug since 2010, replacing opiates (mainly heroin).   
 
The majority of cases have been previously treated.  The proportion of new entrants to treatment 
has fluctuated from 39% in 2004, to a peak of 47% in 2009 and down to 40% in 2014. 
 
The majority of OST clients receive methadone in specialist outpatient clinics, with a smaller number 
receiving it from specialist GPs and a yet smaller proportion (less than 5%) in prison.  The number 
of clients registered for OST on 31 December each year has increased from 3,689 in 1998 to 9,764 
in 2014. 
1. National profile 
1.1 Policies and coordination  
1.1.1 Main treatment priorities in the national drug strategy 
Treatment and rehabilitation in the National Drugs Strategy  
The current National Drugs Strategy(2009–2016) broadened the approach to treatment and 
rehabilitation beyond tackling the consequences of problem drug use, especially opiates in 
disadvantaged areas, to developing a comprehensive substance treatment service capable of 
dealing with all substances, particularly given the increasing geographic dispersal of problem drug 
use (including opiates), the increased prevalence of polydrug use and cocaine use, the increasing 
strength of cannabis, as well as the pervasive misuse of alcohol and the level of misuse of 
prescription drugs in society (Department of Community 2009). 
 
The Steering Group that developed the National Drugs Strategy was also conscious of the need to 
bring greater coherence and co-ordination to alcohol and drug issues at a policy, planning and 
operational level. In this context, the Group strongly endorsed the approach of the Health Service 
Executive (HSE), which was reorienting its addiction services towards polydrug use (including 
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alcohol), and using the four-tiered model as the national framework through which to deliver 
services. The integration of treatment services within the context of the National Drugs Strategy 
relates to the integration of addiction services and the development of appropriate pathways to and 
from general health service provision. 
 
Priorities in relation to treatment and rehabilitation in the National Drugs Strategy 
The overall strategic objective and aims, and operational targets and key performance indicators, 
set in the National Drugs Strategy, including those for Treatment and Rehabilitation, are outlined in 
Section 1.1.1 of the national report for 2015 - policy.  
 
Below are the ‘priorities’ for treatment and rehabilitation services between 2009 and 2016 as set out 
in the National Drugs Strategy, together with progress in delivering on the priorities.  This 
information is taken from the annual progress report on the implementation of the actions in the 
National Drugs Strategy (NDS) in 2014 (Department of Health 2015). 
 
Development of general problem substance use services 
 Develop an integrated national treatment and rehabilitation service for all substances, using a 4-
tier model approach, underpinned by an appropriate clinical and organisational governance 
regime  
Action 32 in the NDS: People who present for addiction treatment are offered a range of 
interventions including initial assessment, comprehensive assessment, Minnesota Programme, 
brief intervention, individual counselling etc. HSE Substance Misuse services provide care and 
onward referral to other statutory and voluntary groups where appropriate (see Section T1.1.2 
below).  
 Maximise operational synergies between Drug Addiction Services, Alcohol Treatment & 
Rehabilitation Services, General Hospital Services and Mental Health Services  
Action 33 in the NDS: Each client receives a personalised care plan based on their individual 
needs, including mental health needs.  
 Expand the availability of detox facilities, opiate substitution services, under-18 services and 
needle exchange services where required 
Action 34 in the NDS: The progress report reported on national availability of detox facilities, 
OST, under-18 services and needle exchange services.  The most recent data are provided 
below (Detox. 1.2.4 and 1.4.3, and OST 1.4.5–8 and 2.1), and in the national report for 2015 - 
harms and harm reduction (needle exchange 1.5.2–3 and 2.1). 
 Implement the recommendations of the Report of the Working Group on Drugs Rehabilitation, 
and the Report of the HSE Working Group on Residential Treatment & Rehabilitation 
(Substance Abuse)  
 
Action 32 in the NDS:  The implementation of the National Drugs Rehabilitation Framework 
(NDRF) has been a priority for the HSE in its 2014 and 2015 service plans. Engagement with the 
Rehabilitation Framework is also a requirement in all Task-Force-funded treatment rehabilitation 
projects. The number of residential beds has increased significantly since 2007, when the Report 
of the HSE Working Group on Residential Treatment and Rehabilitation was published 
(O'Gorman and Corrigan 2008), largely owing to the increased provision of beds in community-
based residential facilities. HSE areas have developed structured funding/referral process for 
service users looking to access residential treatment within their areas.   
 Establish a drugs interventions programme, incorporating a treatment referral option, for those 
who come to the attention of the Gardaí due to behaviour caused by substance misuse  
Action 38 in the NDS:  A ‘Pathways to Support’ programme has been developed incorporating a 
treatment referral option for young people arrested by the Gardaí. The Garda Síochána are 
examining how to implement this programme. 
 
Specific Groups 
 Further develop engagement with, and the provision of services for, specific groups including 
Prisoners, Homeless, Travellers, New Communities, LGBTs and Sex Workers  
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Actions 41–44 in the NDS: The treatment and rehabilitation needs of vulnerable groups including 
travellers, LGBTs, new communities and sex workers, as well as other groups such as families 
of drug users, service users and drug users, drug users in prisons, are being addressed on an 
ongoing basis. 
 
Quality and standards framework 
 Develop a clinical and organisational governance framework for all treatment and rehabilitation 
services  
Action 45 in the NDS: A clinical and organisational governance framework for all treatment and 
rehabilitation services has been developed by the Quality Standards Support Project (QSSP) of 
the Ana Liffey Drugs Project with the support of the HSE. The resources and supports can be 
found on line at www.drugs.ie/quality  
 
Training and skills development 
 Develop national training standards for all those involved in the provision of substance misuse 
services, and co-ordinate training provision within a single national substance misuse framework 
 
Action 47 in the NDS: The HSE’s National Addiction Training Programme (NATP) was 
developing a supportive statement for the development of a workforce development plan to 
support staff and ultimately to improve outcomes for service users and their families. The 
voluntary sector, key academic institutions, drugs and alcohol task forces and other relevant 
partners were to be consulted on this in 2015, and this was to be the basis for a national training 
needs analysis also to be carried out in 2015. 
1.1.2 Governance and coordination of drug treatment implementation 
Established by the Health Act 2004, the Health Service Executive (HSE) is responsible for the 
provision of all publicly-funded health and personal social services for everyone living in Ireland. It 
provides an addiction service, including both drugs and alcohol, delivered through Social Inclusion 
Services, which is part of the HSE’s Primary Care Division. This Division promotes and leads on 
integrated approaches to health care at different levels across the statutory and voluntary sectors, 
including the development of integrated care planning and case management approaches between 
all relevant agencies and service providers.  
 
Introduced in 2015, the HSE’s new Accountability Framework makes explicit the responsibilities of 
all HSE managers, including primary care managers, to deliver the targets set out in the HSE’s 
National Service Plan (NSP) and the Primary Care Division Operational Plan (PCD OP). The 
achievement of ‘improved health outcomes for persons with addiction’ is a priority in the 2015 NSP, 
and the related PCD OP lists seven actions associated with this priority (Health Service Executive 
2014). Progress in implementing these actions is reviewed regularly throughout the year, and 
actions to address variances considered. 
 
The HSE supports the non-statutory sector to provide a range of health and personal social 
services, including the drug projects supported by the local and regional drugs and alcohol task 
forces, which receive annual funding of over €20 million annually.  This funding is governed by way 
of Service Arrangements and Grant Aid Agreements.  The HSE’s Primary Care Division assists the 
drugs projects to participate in planning and reporting in line with the monitoring tool developed by 
the National Addiction Advisory Governance Group, and seeks to ensure that funded organisations 
support and promote the aims and objectives of the National Drugs Strategy.  
 
1.1.3 Further aspects of drug treatment governance 
In 1998 a methadone treatment protocol (MTP) was introduced, to ensure that treatment for 
problem opiate use could be provided wherever the demand exists (Methadone Prescribing 
Implementation Committee 2005, Methadone Treatment Services Review Group 1998). New 
regulations pertaining to the prescribing and dispensing of methadone were introduced. General 
practitioners who wish to prescribe methadone in the community must undergo formalised training 
and the number of clients they can treat is capped, depending on experience.  See Section 1.4.8 
below for an account of a review of the MTP and progress in developing national clinical guidelines 
for opiate treatment. 
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The Central Treatment List (CTL) was established under Statutory Instrument No 225 following the 
Report of the Methadone Treatment Services Review Group 1998 (Methadone Treatment Services 
Review Group 1998). This list is a complete register of all patients receiving methadone (for 
treatment of opiate misuse) in Ireland and is administered by the HSE National Drug Treatment 
Centre.1  
1.2 Organisation and provision of drug treatment 
1.2.1 Outpatient drug treatment system – Main providers 
Summary of Table I.2.1: outpatient services are provided through a network of HSE services 
(public) and non-statutory, voluntary agencies (see also 1.1.2 and 1.4 in this workbook).  Many of 
the non-statutory, voluntary agencies are partly funded by the HSE.  There are an unknown number 
of private organisations that also provide outpatient addiction treatment such as counselling.  Very 
few of the private agencies contribute data to the TDI figures.   
 
Some addiction treatment is also provided and/or funded through the Mental Health Division of the 
HSE.   
 
Table I.2.1 Network of outpatient treatment facilities (total number of units)  
 Total number of units National Definition 
(Characteristics/ 
Types of centre  
included within your  
country 
Specialised drug 
treatment centres 
300 Treatment facilities where the clients are treated during the 
day (and do not stay overnight). They may open in the 
evening but where the opening time excludes the night.  
Include OST clinics, counselling, therapeutic day care and 
socio-economic training units 
Low-threshold agencies 75 Aim to prevent and reduce health-related harm associated 
with drug dependence, in particular the incidence of blood-
borne viral infections and overdoses, and to encourage 
active drug users to contact health and social services. May 
provide low dose OST, general medical assistance, brief 
interventions and needle exchange. 
General/ Mental health 
care 
 Provided through the mental health directorate of the HSE 
or funded by the mental health directorate.  Not included in 
the TDI data. 
Prisons  See inpatient facilities 
Other outpatient units 346 Specially trained general practitioners who provide OST in 
primary care 
Other outpatient units   
Source: Standard table 24 
 
1.2.2 Outpatient drug treatment system – Client utilisation 
Summary of Table I.2.2: over 75% of all addiction treatment over the past 11 years has been 
provided by outpatient services.  It is not possible to estimate the total number of clients in the 
national network as there is no information on those centres that do not report to TDI.  However, 
analysis of the TDI data shows that in 2014, 77.7% of all cases were treated in outpatient services.  
                                                          
1
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Only stable opiate substitution treatment (OST) clients are treated by specialised OST GPs in the 
community (see also 1.4.5 below). 
Table I.2.2 Total outpatient treatment provision (number of clients) 
 Total number of clients  National Definition 
(Characteristics) 
Specialised 
drug treatment 
centres 
It is not possible to estimate the 
total number of clients in the 
national network  as there is no 
information on those centres that 
do not report to TDI 
Treatment facilities where the clients are treated during the day 
(and do not stay overnight). They may open in the evening but 
where the opening time excludes the night.  Include OST clinics, 
counselling, therapeutic day care and socio-economic training units 
Low-threshold 
agencies 
It is not possible to estimate the 
total number of clients in the 
national network  as there is no 
information on those centres that 
do not report to TDI 
Aim to prevent and reduce health-related harm associated with 
drug dependence, in particular the incidence of blood-borne viral 
infections and overdoses, and to encourage active drug users to 
contact health and social services. May provide low dose OST, 
general medical assistance, brief interventions and needle 
exchange. 
General/ 
Mental health 
care 
 Provided through the mental health directorate of the HSE or 
funded by the mental health directorate.  Not included in the TDI 
data. 
Prisons n/a See inpatient facilities 
Other 
outpatient units 
It is not possible to estimate the 
total number of clients in the 
national network  as there is no 
information on those centres that 
do not report to TD 
Specially trained general practitioners who provide OST in primary 
care. 
Other 
outpatient units 
  
Source: Standard table 24 
 
1.2.3 Further aspects of outpatient drug treatment provision and utilisation 
General practitioners (GPs) are medical practitioners who treat acute and chronic illnesses and 
provide preventive care and health education for all ages and both sexes.  They may treat drug 
users for their drug problems, in some cases in liaison with outpatient or inpatient drug services, and 
some of them may have a specific training on the treatment of drug users.  Those who have 
completed the specialist training can provide OST to clients who are stable.  For further information, 
see Section 1.4.5 below. 
 
1.2.4 Inpatient drug treatment system – Main providers 
Inpatient addiction treatment services are provided mainly through non-statutory agencies. Most of 
these agencies are partially funded by the HSE Table 1.2.4.  There are two dedicated inpatient HSE 
detoxification units. 
 
The mental health services also provide inpatient addiction treatment in 69 different hospitals.  
Figures from these services are not included in the annual TDI figures. For further information, see 
‘Drug admissions to psychiatric facilities’ in Section 1.2.3 of national report for 2015 - harms and 
harm reduction. 
 
Table I.2.4. Network of inpatient treatment facilities (total number of units)  
 Total number of units National Definition 
(Characteristics/ 
Types of centre  
included within your  
country 
Hospital-based residential 2 Two wards or units in hospitals where the 
clients may stay overnight. Also includes 
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 Total number of units National Definition 
(Characteristics/ 
Types of centre  
included within your  
country 
drug treatment 69 psychiatric hospitals.  Psychiatric 
hospitals do not report to TDI. 
Residential drug treatment  
(non-hospital based) 
 See other inpatient units (below) 
Therapeutic communities  See other inpatient units (below) 
Prisons 33 Includes all addiction treatment provided in 
prisons, whether in-reach services or 
provided by the medical service of the 
prison 
Other inpatient units 48 Defined as centres where the clients may 
stay overnight. They include therapeutic 
communities, private clinics, units centres 
that offer residential facilities.  It is not 
possible to differentiate between 
residential in-patient and therapeutic 
communities so both reported together in 
this section 
Other inpatient units   
Source: Standard table 24 
 
1.2.5 Inpatient drug treatment system – Client utilisation 
It is not possible to estimate the total number of clients in the national in-patient network as there is 
no information on those centres that do not report to TDI (see Table 1.2.5).  However, over the past 
11 years, TDI data have shown that the proportion of clients treated in in-patient facilities (excluding 
prisons) has dropped slightly, from 15.3% in 2004 to 13.5% in 2014.  
 
None of the 69 psychiatric inpatient hospitals described in Section 1.2.5 above report through TDI.  
However, the annual reports on admissions to psychiatric hospitals show that there was a 17% 
decline in overall psychiatric admissions for addiction in the 10 years between 2004 and 2014 (Daly 
and Walsh 2014). 
 
Table 1.2.5 Total inpatient treatment provision (number of clients) 
 Total number of clients  National Definition 
(Characteristics) 
Hospital-based residential drug 
treatment 
 It is not possible to estimate 
the total number of clients in 
the national network  as there 
is no information on those 
centres that do not report to 
TDI 
Two wards or units in 
hospitals where the 
clients may stay 
overnight. Also includes 
69 psychiatric hospitals.  
Psychiatric hospitals do 
not report to TDI. 
Residential drug treatment 
(non-hospital based) 
n/a See other inpatient units 
(below) 
Therapeutic communities n/a See other inpatient units 
(below) 
Prisons It is not possible to estimate 
the total number of clients in 
the national network  as there 
is no information on those 
centres that do not report to 
Includes all addiction 
treatment provided in 
prisons, whether in-reach 
services or provided by 
the medical service of the 
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TDI prison 
Other inpatient units It is not possible to estimate 
the total number of clients in 
the national network  as there 
is no information on those 
centres that do not report to 
TDI 
Defined as centres where 
the clients may stay 
overnight. They include 
therapeutic communities, 
private clinics, units 
centres that offer 
residential facilities.  It is 
not possible to 
differentiate between 
residential in-patient and 
therapeutic communities 
so both reported together 
in this section 
Other inpatient units   
Source: Standard table 24 
1.3  Key data 
1.3.1 Summary table of key treatment related data and proportion of treatment demands by 
primary drug 
Opiates (mainly heroin) and cannabis are the two main drugs for which cases sought treatment in 
Ireland in 2014.  
 
Just under half (49.8%) of all cases entering treatment in 2014 reported opiates as their main 
problem drug (see Figure 1.3.1 and Table 1.3.1).  This is similar to 2013, when 51.3% of all cases 
entering treatment reported opiates as their main problem drug.  Heroin is the main drug in this 
category, representing 89.2% of all those reporting an opiate, similar to 2013 when 89.1% reported 
heroin as their opiate.   
 
The majority (72.8%) of those reporting an opiate as their main problem drug had been previously 
treated, compared to 73.9% in 2013. 
 
 
Figure I  Proportion of treatment demand, by primary drug, 2014 
Source: TDI 
 
 
Table 1.3.1 Summary table – Clients in treatment 
  
Opiates (mainly heroin) 4,745 
49.8 
0.6 8.7 
0.6 
27.8 
12.5 
Opiates
Ecstasy
Cocaine
Amphetamines
Cannabis
Other drugs
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Cannabis 2,645 
Other drugs (mainly 
benzodiazepines) 
1,194 
Cocaine 828 
Source: ST24 and TDI 
 Number of clients 
Total clients in treatment                              9,523 (source TDI) 
Total OST clients                                               9,764 (source Central Treatment List) 
Total All clients entering 
treatment                                          
Data on OST and TDI are from different sources, collected using 
different methodology, also with some duplication, so therefore 
cannot be combined or compared meaningfully 
Source: ST24 and TDI 
 
 
The next most common drug reported was cannabis.  Twenty-nine per cent of cases reported 
cannabis as their main problem drug, identical to the percentage reported in 2013. The majority 
(64.1%) of those reporting cannabis as their main problem drug had never been treated before, 
compared to 65.0% in 2013. 
 
Cocaine was the next most illicit common drug reported, with 8.7% in 2014, compared to 7.8% in 
2013.  Similar proportions of cases presenting had never been previously treated (51.2%) and had 
been previously treated (43.2%).  This is the same pattern as in 2013 (47.1% and 47.6% 
respectively, with treatment status unknown for 5.3%). 
 
Amphetamines and ecstasy make up a very small proportion of the main problem drugs reported, 
0.6% and 0.6%.  This is almost identical to 2013, when 0.6% of cases reported amphetamines as 
their main problem drug, and 0.5% reported ecstasy as their main problem drug. 
 
Benzodiazepines comprise the majority of the ‘other drugs’ category.  Seventy-seven per cent of 
cases reported benzodiazepines as their main problem drug in 2014, compared to 81.6% in 2013. 
There were more cases in 2014 reporting a benzodiazepine as their main problem drug (9.6%) than 
reporting cocaine (8.7%).   A slightly lower proportion (49.1%) of these cases in 2014 were 
previously treated, compared to 51.2% in 2013. 
 
1.3.2 Distribution of primary drug in the total population in treatment 
The results shown below describe the characteristics of young people attending the Matt Talbot 
Services in Cork between January 2005 and August 2011, and their patterns of drug use, in 
particular benzodiazepines (Murphy K, et al. 2014).   The authors retrospectively reviewed client 
notes and extracted data of interest from the notes.  Collecting complete data for each participant on 
all the variables of interest was not possible, and so the denominators for many characteristics vary 
depending on the completeness of the data relating to the individual variables. As a result, the 
proportions reported in the following account also vary. 
 
A total of 198 client files were included in the study.  Almost all the clients included in the study were 
male (98%).  This is because originally the service was just for males and only started to accept 
females for treatment in 2010. The average age of clients was 16.4 years (range 13 to 21 years).  
Most clients (55/113, 49%) were referred by the Department of Justice, either through Juvenile 
Liaison Officers or Probation Officers.   
 
Almost all (182/187, 99%) had ever drunk alcohol, with half starting at 13 years or younger.  After 
alcohol, most had also used cannabis (170/181, 94%) and tobacco (153/165, 93%). The next most 
prevalent drug ever used was cocaine (88/162, 54%) and then benzodiazepines (80/157, 51%).  
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Of the 80 clients who reported ever using benzodiazepines, one third (28/80, 35%) had used them 
at least once a week, and half (43/77, 56%; data on time of last use were not available for three) 
had used them in the previous month (classified as regular users).  The average age of first use of 
benzodiazepines was 14.9 years.   
 
The characteristics of regular benzodiazepine users were compared with non-regular users.  
Regular users were significantly more likely to be regular users of other drugs.  There were also 
statistically significant differences between behavioural and physical symptoms. Regular users were 
more likely to report paranoia, loss of interest in sports or hobbies, attention-seeking behaviour, 
pale/white skin, and vomiting.  Skin pallor is well-known to be associated with benzodiazepine 
withdrawal and can last several weeks. 
 
The study had limitations.  Information was missing for many of the variables because data were 
extracted retrospectively from client notes so the results were not comprehensive. More data on 
psychosocial and clinical systems, which could have been collected through a tailored 
questionnaire, would have helped to provide a more comprehensive understanding of the clients.   
 
The authors note that benzodiazepines had been used by many of the young people attending the 
service over the period and that many of them were regular users.  Regular users were more likely 
to suffer from known side-effects of the drug such as paranoia.  The authors urged greater 
awareness among health professionals of the acute and chronic negative consequences associated 
with benzodiazepine use in young people as described in their study. 
 
1.3.3 Further methodological comments on the Key Treatment-related data 
Coverage of the National Drug-Related Treatment System (NDTRS), through which the TDI data 
are reported, has remained consistently high at over 70%. However, as there is no national unique 
health identifier, duplication can only be controlled for within treatment centres, not at a national 
level.  Therefore a person may be counted more than once if they attend more than one treatment 
centre within the same calendar year.   
 
NDTRS data undergo at least two levels of cleaning and validation before being submitted to the 
EMCDDA.  There is on-going feedback of problems and training to ensure the completeness and 
validity of the data. 
 
1.4 Treatment modalities 
1.4.1 Outpatient drug treatment services 
The types of treatment and services offered vary depending on the service.  The majority of OST is 
provided by designated HSE clinics, which often also offer other specialist services including 
psychiatry, counselling, social services and general medical activities, e.g. vaccinations (see also 
Section 1.4.5 below).  Other services, which do not offer OST, may provide a wide variety of 
treatments including counselling, group therapy, socio-economic training, complementary therapies, 
relapse prevention etc. 
1.4.2 Further aspect of available outpatient treatment services 
In recent years, people have been able to undergo methadone and benzodiazepine detoxification in 
the community, rather than having to wait for admission to an in-patient unit, supported by outpatient 
services using a set of standardised protocols (Dermody and Lyons 2012). 
1.4.3 Inpatient drug treatment services 
Residential drug treatment (non-hospital based) including therapeutic communities 
These services are provided mainly by non-statutory, voluntary services and the ideology behind 
each varies according to the agency running the service.  Some require clients to be drug-free and, 
depending on the service, may also require them to be off methadone.  These types of service offer 
a wide range of treatments including counselling, group therapy, social/occupational activities, 
family therapy, complementary therapies and aftercare. 
 
Detoxification 
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There are two dedicated HSE hospital in-patient detoxification units. Some residential centres 
provided by voluntary/non-statutory services also offer detoxification as part of their suite of 
treatments.   
 
Prison 
Addiction treatment in prison is provided by the prison medical service. Treatments include 
detoxification, OST and psychiatric treatment, while counselling is provided by in-reach services. 
 
In-patient psychiatric hospitals 
Addiction treatment provided in psychiatric hospitals includes psychiatric treatment, detoxification 
and any other medical treatment as required by the client. 
 
1.4.4 Treatment outcomes and recovery from problem drug use 
An evaluation of an educational substance use recovery and fitness programme, ‘The Boxing Clever 
programme’, found that the programme had a number of positive outcomes (Morton, et al. 2015).  
The programme aimed to support participants to develop more resilient identities, while encouraging 
educational achievement, physical wellness and reduction in harmful or risky behaviours. The 
authors of the report concluded that their research not only demonstrated the important role 
education and sport can play in substance use rehabilitation, but also the importance of inter-
agency work in achieving the goals of rehabilitation and reintegration. Some of the positive 
outcomes included: 
 
 Sport and physical exercise helped improve mood. 
 The majority of participants completing the programme maintained their drug-free status or 
reduced their drug use, and attributed this to their participation in the programme. 
 The programme supported and facilitated the majority of participants to achieve a Quality and 
Qualifications Ireland (QQI) minor award at levels 4 and 5, which is seen as a vehicle for further 
education. 
 The California Assessment of Stigma Change (CASC) element of the programme was pivotal in 
supporting participants to understand substance use within their family of origin and the wider 
community. 
 
The authors identified two major limitations to their research: (1) the sample size was small, with 
only 17 programme participants engaging in the research process, and (2) the research considered 
the immediate impacts and outcomes for participants. The authors called for further research to 
consider the ‘long term impact and outcome of programmes that seek to build social and human 
capital, particularly those that utilise both fitness and education in the programme delivery’ (pp. 57–
58). 
 
1.4.5 Main providers/organisations providing Opioid substitution treatment 
Outpatient methadone maintenance treatment (MMT) for problem opiate users is provided only 
through HSE drug treatment clinics, satellite clinics or through specialised GPs in the 
community.  MMT is provided free of charge.  Under the methadone treatment protocol (MTP), GPs 
in the community are contracted to provide MMT at one of two levels – Level 1 or Level 2.   Level 1 
GPs are permitted to maintain methadone treatment for problem opiate users who have already 
been stabilised on a methadone maintenance programme. Each GP qualified at this level is 
permitted to treat up to 15 stabilised problem opiate users. Level 2 GPs are allowed to both initiate 
and maintain methadone treatment. Each GP qualified at this level may treat up to 35 problem 
opiate users. Practices where two Level 2 GPs are practising are permitted to treat up to 50 problem 
opiate users.  These levels are currently being reviewed and may be revised upwards in the future. 
 
In 2014, 54.6% of patients were receiving treatment in specialist outpatient clinics, 40.5% from GPs 
and 4.8% in prison. The proportion of clients receiving treatment from GPs has increased slowly but 
steadily over the years, from 31.7% in 2001 to 40.6% in 2014.  The proportion of clients receiving 
treatment in specialist outpatient clinics has decreased, from 59.0% in 2008 to 54.6% in 2014. 
1.4.6 Number of clients in OST 
Almost all clients receive methadone as their opiate substitute.  Buprenorphine in combination 
preparations is not routinely available in Ireland and less than 1% of clients receive it.  The drug 
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suboxone, a combination of buprenorphine and naloxone, was licensed for use in 2006 in Ireland as 
an alternative to methadone for opiate dependency. In 2007 an expert group was set up to examine 
the regulatory framework for products containing buprenorphine/naloxone and buprenorphine-only 
(Expert Group on the Regulatory Framework 2011). The expert group considered a number of 
relevant documents, including an evaluation of a feasibility study on the use of suboxone in Ireland 
(Fitzgerald 2011).  The group concluded that methadone is the drug of first choice for treating opiate 
dependency in Ireland, but that buprenorphine/naloxone may be appropriate for some patient 
cohorts in certain circumstances: 
 patients already receiving treatment with buprenorphine/naloxone; 
 patients with a specific medical condition where methadone is contraindicated, for example 
prolonged QT interval, an abnormal heart rhythm; 
 patients who have never been prescribed methadone before, especially young patients, where 
detoxification is a primary goal of treatment; 
 patients whose main problem drug is codeine or another pharmaceutical opioid; or 
 patients whom the prescriber believes to have been stable for at least six months, particularly in 
regard to employment or education, and committed to compliance with the treatment. 
 
The number of clients registered for MMT on 31 December each year is reported by the Central 
Treatment List (CTL) (see also Figure 2.1.2 in 2.1 below and Standard Table 24).  On 31 December 
2014, 9,764 clients were registered for MMT (including those receiving methadone in prison) 
(personal communication, Caroline Comar, CTL). This is a slight increase (1.3%) on the previous 
year. 
1.4.7 Characteristics of clients in OST 
Of the 9,764 clients registered on the Central Treatment List (CTL) on 31 December 2014, the 
majority were male (69.2%).  The proportion of men registered on the CTL has remained largely 
unchanged since 1998, never dropping below 66.5% or rising above 69.2%.   In 2014 the largest 
proportion of clients (29.1%) were aged between 35 and 39 years, followed by 22.7% aged 30 to 34 
years, then 17.7% aged 40 to 44 years, and 10.5% aged 25 to 29 years.  This is the same trend 
recorded in 2013. No other characteristics are available for analysis from the CTL data. 
Concurrent OST and benzodiazepine use 
A recent study found that 84% of patients attending an opiate substitution treatment (OST) clinic in 
Dublin tested positive for benzodiazepines (Gilroy, et al. 2014).  During the study period, 137 
patients attended the clinic, of whom 115 (84%) tested positive for benzodiazepines.   
 
The majority of participants were men (81%) and the median age was 35 years.  Most (71%) 
reported daily or almost daily use of benzodiazepines.  Participants reported using between zero 
and 24 tablets daily, but the majority (68%) used between zero and five tablets per day.  Eighteen 
per cent reported using an average of 10 to 24 tablets per day.  Just over half (51%) reported that 
they had maintained their reported pattern of use for less than one year.  Nearly a third (30%) 
reported that they had maintained their pattern of use for three to five years.  Diazepam was the 
most common type of benzodiazepine (94%), followed by flurazepam (35%).  The majority (65%) of 
participants only used one type while the remainder (35%) used two or three types.  Almost all 
participants (97%) used benzodiazepines orally, with only 3% injecting.  Almost one third (30%) 
used benzodiazepines along with other drugs (48% alcohol, 39% heroin, 9% crack cocaine and 4% 
cannabis). 
 
Half of all participants (50%) had a prescription for their benzodiazepines. Those who used illicit 
(street) benzodiazepines spent on average €40 a week (range €2 to €300).  Most participants (87%) 
who only used prescribed benzodiazepines consumed one to five tablets per day while those who 
used illicit or mixed sources consumed on average a higher number of tablets per day.   
 
Characteristics of prisoners receiving OST 
See Galander et al. (Galander, et al. 2014) in Section 1.3.3 in national report for 2015 - prison. 
 
14 
1.4.8 Further aspect on organisation, access and availability of OST 
Development of clinical guidelines for opiate treatment  
In April 2014 a draft of the clinical guidelines for opiate treatment was distributed to a wider group 
for consultation; the results of this consultation are still awaited (personal communication Suzi 
Lyons, Health Research Board). See Chapter 5.2.2.1 of the 2013 National Report (Health Research 
Board 2013) for a brief outline of the expected contents of the guidelines. 
 
Relapse in opioid substitution treatment (OST)  
A cross-sectional study of clients attending a large methadone clinic in Dublin was conducted in 
March 2012, with the aim of identifying the factors associated with relapse from OST and the 
reasons for the relapse (Darker, et al. 2015). 
 
Almost two thirds (189, 63%) of the total 300 clients attending the clinic in March 2012 participated 
in the study.  Participants were categorised into two groups: those who had a break in their OST 
(n=87, 46%) and those with no break in their OST (n=102, 54%).   
 
The demographic profile of both groups was relatively similar. The majority were male and single. 
There was a very high level of unemployment in both groups, over 94%.  A higher proportion of 
those with a break in OST were homeless (7.6% versus 1.1%), and co-habiting was more common 
among those with a break (34.5% versus 17.6%).  The median age of those with a break was 33 
years, slightly younger than those with no break (36 years). 
 
Clinical factors were also similar in both groups, although just over half (52.3%) of those with a 
break in OST were taking a methadone dose of 60mls or less compared with only 32.4% of those 
with no break. 
 
Of those who ever had a break in OST, most only reported one break (83.9%, 73).  The length of 
break varied from less than one month to 18 months but the median duration was two months. 
Females were more likely to have shorter breaks compared to males but no other factors were 
found to be significant in relation to duration of OST. 
 
Statistical analysis showed that age was the only demographic factor significantly associated with 
not having a break: older clients were less likely to have a break in OST. Three clinical factors were 
significantly associated with not having a break: current methadone dose higher than 60 mls, longer 
time in treatment, and less than one year in current treatment episode. In addition, although the 
numbers were small, nine out of the ten clients with a prescription for anti-psychotic medicine did 
not report a break in treatment. 
 
The most common reasons for breaks in OST reported by the study participants were:  
 21.8% – relapse to drug use, 
 13.7% – ‘fed up with methadone’ and wanting to detox off, 
 11.4% – imprisonment or problems with the police, 
 10.3% – difficulty with travelling to the clinic or clinic times, 
 8.0% – being ‘clean’, 
 6.8% – being out of the country, 
 6.8% – emotional events, e.g. family bereavements, 
 3.4% – not wanting to take methadone while pregnant, and 
 3.4% – illness. 
 
Reasons given for regular attendance were: 
 37.5% – wanting to get or stay ‘clean’, 
 16.1% – wanting to avoid sickness, 
 13.9% – methadone dependence, 
 10.2% – level of services provided by clinic, 
 5.1% – withdrawal symptoms, 
 5.1% – support from family members, and  
 4.4% – only having to attend a few times a week. 
 
The findings of this study in relation to older age and higher methadone dose being predictors of 
retention in OST correspond with the findings of other national and international research studies.  
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The most common reason for break in treatment reported in other studies has also been relapse to 
drug use.  While the study confirms that higher methadone doses may improve retention in 
treatment, the authors recommend that this should be balanced against the known side-effects of 
increasing the dosage, e.g. constipation, hypotension, drowsiness and increased dependence. 
 
 
2. Trends  
2.1 Long term trends in numbers of clients entering treatment and in OST 
New treatment entrants (Figure 2.1.1) 
In 2014 there were 3,774 new entrants recorded in the NDTRS (see also TDI table).  This 
represents an increase of 8.8%, compared to 3,470 in 2013. New treatment entrants represented 
39.6% of all cases in 2014.  The proportion of new entrants in treatment has fluctuated slightly over 
the 10-year reporting period, from 39.3% in 2004 to a peak of 47.2% in 2009 and back to 39.6% in 
2014.   
 
Between 2006 and 2010 opiates (mainly heroin) were the main problem drug reported by new 
entrants, but this was superseded by cannabis in 2011, and this trend continued until 2014 Cocaine 
peaked among new entrants in 2009 at 19.0%, dropping steadily thereafter until 2012 and then 
increasing again to 51.2% in 2014.  In 2004, 5.6% of new entrants reported ecstasy as their main 
problem drug, but it dropped to 1.0% in 2014.  Both amphetamines and ecstasy are reported only 
very rarely by new entrants to treatment. 
In 2014, ‘other drugs’, mainly benzodiazepines, were the third largest group of drugs reported by 
new entrants as their main problem drug.  
 
Source: TDI 
Figure 2.1.1 Trends in number of first-time clients entering treatment, by primary drug, 2004–2014 
All treatment entrants (Figure 2.1.2) 
In 2014, a total of 9,523 entrants were recorded in the NDTRS (see also TDI).  This represents an 
increase of 9.7%, compared to 8,684 in 2013. Of these, the majority had been previously treated 
(55.4%).  
 
In 2014 opiates, mainly heroin, were the main problem drug used by entrants to treatment. The 
absolute number presenting for problem opiate use increased between 2004 and 2010, dropped in 
the two subsequent years, and then increased slightly in 2013.    
However, looking at the proportion of opiate cases compared to the total, it has decreased year-on-
year over the past 11 years, from 64.6% in 2004 to 51.6% in 2012, when it plateaued, but still with a 
slight decrease, in 2013 to 51.3%.  In 2014 a further decrease to 49.8% was observed. 
 
Between 2004 and 2014, cannabis was consistently reported as the second most common problem 
drug, with the proportion increasing slightly from 21.2% in 2004 to 27.8% in 2014.  The numbers 
presenting for treatment for problem cocaine use was highest in 2007 at 13.3%, dropping steadily 
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then until 2012 when it stabilised, but the number of cases increased again in 2014.  Both 
amphetamines and, to a lesser extent ecstasy, are reported very rarely by entrants to treatment. 
 
In 2014, ‘other drugs’, mainly benzodiazepines, were the third largest group of problem drugs 
reported.   
 
Please note the data reported through TDI are a different selection from the data reported in the 
regular NDTRS web updates and interactive tables, so figures reported through these sources will 
differ slightly. 
 
 
Source:  TDI 
Figure 2.1.2  Trends in number of all clients entering treatment, by primary drug, 2002–2014 
Opioid substitution treatment (OST) clients (Figure 2.1.3) 
The number of clients registered for OST on 31 December each year reported by the Central 
Treatment List (CTL) has increased from 3,689 in 1998 to 9,764 in 2014 (personal communication, 
Caroline Comar, CTL).  The increase is due to the inception of the service in 1998, with year-on-
year more clients coming to treatment and more facilities becoming available (Farrell and Barry 
2010).  Since 2008 the rate of increase has been less than 4% annually. This may reflect a change 
in patterns of drug use, but analysis of other sources, including treatment data and numbers of 
problem drug users, is necessary to explore this further.  
 
The proportion of older clients has fluctuated.  In 1998, the proportion of clients aged 45 years or 
older was 18.1%, dropping steadily to a low of 9.1% in 2009 and then increasing to 16.4% in 2014.  
This trend is mirrored by the proportion of younger clients aged 25 years or younger, albeit smaller 
numbers.  The proportion of this group increased from 0.1% in 2000 (none were registered before 
that) to a peak of 6.7% in 2010.  Since then the proportion has decreased year-on-year to 3.0% in 
2014. 
 
 
0
1000
2000
3000
4000
5000
6000
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Opiates
Cannabis
Other drugs
Cocaine
Amphetamines
Ecstasy
17 
 
Source: ST 24 (Central Treatment List)  
Figure 2.1.3  Trends in number of clients in opioid substitution treatment, 2004–2014 
 
3. Sources and references 
 
3.1 Sources 
Data on drug treatment in Ireland are collected through two national data collection tools – the 
Central Treatment List (CTL) and the National Drug Treatment Reporting System (NDTRS).  
 
The CTL is an administrative database to regulate the dispensing of methadone treatment. 
Established under Statutory Instrument No 225 (Minister for Health and Children 1998), it is a 
complete register of all patients receiving methadone (as treatment for problem with opiate use) in 
Ireland. When a person is considered suitable for methadone detoxification, stabilisation or 
maintenance, the prescribing doctor notifies the CTL by completing an entry form, a unique number 
is allocated to the client and a treatment card is issued for clients when dispensed in community 
pharmacies. Numbers on the CTL are published annually by the Health Service Executive and 
Health Research Board.  
 
The NDTRS is a national epidemiological database which provides data on treated drug and alcohol 
misuse in Ireland. The NDTRS collects data from both public and private outpatient services, 
inpatient specialised residential centres and low-threshold services.  For the purposes of the 
NDTRS, treatment is broadly defined as ‘any activity which aims to ameliorate the psychological, 
medical or social state of individuals who seek help for their substance misuse problems’.  The 
NDTRS is a case-based, anonymised database. It is co-ordinated by staff at the Health Research 
Board (HRB) on behalf of the Department of Health.  
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European Monitoring Centre for Drugs and Drug Addiction 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a decentralised EU 
agency based in Lisbon.  The EMCDDA provides the EU and its Member States with information on 
the nature, extent, consequences and responses to illicit drug use. It supplies the evidence base to 
support policy formation on drugs and addiction in both the European Union and Member States.   
There are 30 National Focal Points that act as monitoring centres for the EMCDDA.  These focal 
points gather and analyse country data according to common data-collection standards and tools 
and supply these data to the EMCDDA. The results of this national monitoring process are supplied 
to the Centre for analysis, from which it produces the annual European drug report and other 
outputs. 
 
The Irish Focal Point to the EMCDDA is based in the Health Research Board.  The focal point 
writes and submits a series of textual reports, data on the five epidemiological indicators and supply 
indicators in the form of standard tables and structured questionnaires on response-related issues 
such as prevention and social reintegration.  The focal point is also responsible for implementing 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances. 
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